BioLife (BLFS) Officer Disposes 10,000 Shares; Post-Sale Holdings 124,618

Rhea-AI Filing Summary

Todd Berard, Chief Marketing Officer of BioLife Solutions, sold 10,000 shares of BLFS common stock on 08/25/2025 at a weighted average price of $25.53 per share (individual trade prices ranged from $25.46 to $25.63). After the sale, the reporting person beneficially owned 124,618 shares. The Form 4 was signed on 08/27/2025 and discloses the sale as a direct disposition. The filer notes the reported price is a weighted average from multiple transactions and offers to provide the number of shares sold at each price upon request.

Positive

• None.

Negative

• Reported direct sale of 10,000 shares, reducing insider holdings to 124,618 shares
• Sale occurred at a weighted average price of $25.53, indicating insider disposition rather than acquisition

Insights

Financial Analyst

Insider sale disclosed: 10,000 shares sold, leaving 124,618 held; transaction is a direct disposition reported on Form 4.

The filing documents a routine insider sale rather than an acquisition or derivative transaction. The sale quantity (10,000 shares) and the post-sale holding (124,618 shares) are explicit and allow investors to update insider-holding tables. The weighted average price of $25.53 and the disclosed trade-range provide precise execution context. Absent additional context such as a change in role, company guidance, or multiple concurrent insider filings, this single Form 4 is a factual disclosure with limited standalone impact on valuation models.

Corporate Governance Expert

Officer sale properly reported on Form 4; disclosure complies with Section 16 reporting requirements.

The report correctly identifies the reporting person as an officer (Chief Marketing Officer) and records a direct sale with a clear post-transaction beneficial ownership figure. The explanatory note clarifies that the reported price is a weighted average from multiple transactions and offers to provide per-price allocation on request, which enhances transparency. The filing includes a manual signature and date, satisfying procedural Form 4 requirements. No amendments or 10b5-1 plan notation are present in the form content provided.

08/27/2025 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Berard Todd

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		S		10,000	D	$25.53(1)	124,618	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.46 to $25.63, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Remarks:

	/s/ Todd Berard	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BLFS insider Todd Berard report on Form 4?

Todd Berard reported a direct sale of 10,000 shares of BioLife Solutions (BLFS) on 08/25/2025 and now beneficially owns 124,618 shares.

At what price were the BLFS shares sold by the reporting person?

The weighted average price was $25.53 per share, with individual trade prices ranging from $25.46 to $25.63 as disclosed in the filing.

What is Todd Berard's role at BLFS as listed on the Form 4?

Chief Marketing Officer is the relationship to the issuer specified on the Form 4.

When was the Form 4 transaction dated and when was the form signed?

Transaction date: 08/25/2025. Signature date on the Form 4: 08/27/2025.

Does the filing indicate a 10b5-1 trading plan or an amendment?

No 10b5-1 plan indication or amendment date is shown in the content provided.